将新方法纳入非临床药物安全性评估监管。

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Altex-Alternatives To Animal Experimentation Pub Date : 2023-01-01 Epub Date: 2023-01-18 DOI:10.14573/altex.2212081
Jan Turner, Pandora Pound, Carla Owen, Isobel Hutchinson, Marina Hop, David Y S Chau, Lady V Barrios Silva, Mike Coleman, Audrey Dubourg, Lorna W Harries, Victoria Hutter, J Gerry Kenna, Volker M Lauschke, Winfried Neuhaus, Clive Roper, Paul B Watkins, Jonathan Welch, Laura R Alvarez, Katy Taylor
{"title":"将新方法纳入非临床药物安全性评估监管。","authors":"Jan Turner, Pandora Pound, Carla Owen, Isobel Hutchinson, Marina Hop, David Y S Chau, Lady V Barrios Silva, Mike Coleman, Audrey Dubourg, Lorna W Harries, Victoria Hutter, J Gerry Kenna, Volker M Lauschke, Winfried Neuhaus, Clive Roper, Paul B Watkins, Jonathan Welch, Laura R Alvarez, Katy Taylor","doi":"10.14573/altex.2212081","DOIUrl":null,"url":null,"abstract":"<p><p>New approach methodologies (NAMs) based on human biology enable the assessment of adverse biological effects of pharmaceuticals and other chemicals. Currently, however, it is unclear how NAMs should be used during drug development to improve human safety evaluation. A series of 5 workshops with 13 international experts (regulators, preclinical scientists, and NAMs developers) was conducted to identify feasible NAMs and to discuss how to exploit them in specific safety assessment contexts. Participants generated four “maps” of how NAMs can be exploited in the safety assessment of the liver, respiratory, cardiovascular, and central nervous systems. Each map shows relevant endpoints measured and tools used (e.g., cells, assays, platforms), and highlights gaps where further development and validation of NAMs remains necessary. Each map addresses the fundamental scientific requirements for the safety assessment of that organ system, providing users with guidance on the selection of appropriate NAMs. In addition to generating the maps, participants offered suggestions for encouraging greater NAM adoption within drug development and their inclusion in regulatory guidelines. A specific recommendation was that pharmaceutical companies should be more transparent about how they use NAMs in-house. As well as giving guidance for the four organ systems, the maps provide a template that could be used for additional organ safety testing contexts. Moreover, their conversion to an interactive format would enable users to drill down to the detail necessary to answer specific scientific and regulatory questions.</p>","PeriodicalId":51231,"journal":{"name":"Altex-Alternatives To Animal Experimentation","volume":"40 3","pages":"519-533"},"PeriodicalIF":4.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.\",\"authors\":\"Jan Turner, Pandora Pound, Carla Owen, Isobel Hutchinson, Marina Hop, David Y S Chau, Lady V Barrios Silva, Mike Coleman, Audrey Dubourg, Lorna W Harries, Victoria Hutter, J Gerry Kenna, Volker M Lauschke, Winfried Neuhaus, Clive Roper, Paul B Watkins, Jonathan Welch, Laura R Alvarez, Katy Taylor\",\"doi\":\"10.14573/altex.2212081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>New approach methodologies (NAMs) based on human biology enable the assessment of adverse biological effects of pharmaceuticals and other chemicals. Currently, however, it is unclear how NAMs should be used during drug development to improve human safety evaluation. A series of 5 workshops with 13 international experts (regulators, preclinical scientists, and NAMs developers) was conducted to identify feasible NAMs and to discuss how to exploit them in specific safety assessment contexts. Participants generated four “maps” of how NAMs can be exploited in the safety assessment of the liver, respiratory, cardiovascular, and central nervous systems. Each map shows relevant endpoints measured and tools used (e.g., cells, assays, platforms), and highlights gaps where further development and validation of NAMs remains necessary. Each map addresses the fundamental scientific requirements for the safety assessment of that organ system, providing users with guidance on the selection of appropriate NAMs. In addition to generating the maps, participants offered suggestions for encouraging greater NAM adoption within drug development and their inclusion in regulatory guidelines. A specific recommendation was that pharmaceutical companies should be more transparent about how they use NAMs in-house. As well as giving guidance for the four organ systems, the maps provide a template that could be used for additional organ safety testing contexts. Moreover, their conversion to an interactive format would enable users to drill down to the detail necessary to answer specific scientific and regulatory questions.</p>\",\"PeriodicalId\":51231,\"journal\":{\"name\":\"Altex-Alternatives To Animal Experimentation\",\"volume\":\"40 3\",\"pages\":\"519-533\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Altex-Alternatives To Animal Experimentation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14573/altex.2212081\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Altex-Alternatives To Animal Experimentation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14573/altex.2212081","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

基于人体生物学的新方法(NAMs)能够评估药物和其他化学品的不良生物效应。然而,目前尚不清楚在药物开发过程中应如何使用新方法来改进人体安全性评估。我们与 13 位国际专家(监管人员、临床前科学家和 NAMs 开发人员)举行了 5 次系列研讨会,以确定可行的 NAMs,并讨论如何在特定的安全评估环境中加以利用。与会者绘制了四张 "地图",说明如何在肝脏、呼吸系统、心血管系统和中枢神经系统的安全性评估中利用非杀伤性物质。每张地图都显示了测量的相关终点和使用的工具(如细胞、化验、平台),并强调了仍需进一步开发和验证 NAMs 的差距。每张地图都针对该器官系统安全评估的基本科学要求,为用户选择适当的 NAM 提供指导。除了绘制地图之外,与会者还就鼓励在药物开发过程中更多地采用 NAM 并将其纳入监管指南提出了建议。其中一项具体建议是,制药公司在内部如何使用 NAM 方面应该更加透明。除了为四个器官系统提供指导外,地图还提供了一个模板,可用于其他器官的安全性测试。此外,将其转换为交互式格式将使用户能够深入了解回答特定科学和监管问题所需的细节。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Incorporating new approach methodologies into regulatory nonclinical pharmaceutical safety assessment.

New approach methodologies (NAMs) based on human biology enable the assessment of adverse biological effects of pharmaceuticals and other chemicals. Currently, however, it is unclear how NAMs should be used during drug development to improve human safety evaluation. A series of 5 workshops with 13 international experts (regulators, preclinical scientists, and NAMs developers) was conducted to identify feasible NAMs and to discuss how to exploit them in specific safety assessment contexts. Participants generated four “maps” of how NAMs can be exploited in the safety assessment of the liver, respiratory, cardiovascular, and central nervous systems. Each map shows relevant endpoints measured and tools used (e.g., cells, assays, platforms), and highlights gaps where further development and validation of NAMs remains necessary. Each map addresses the fundamental scientific requirements for the safety assessment of that organ system, providing users with guidance on the selection of appropriate NAMs. In addition to generating the maps, participants offered suggestions for encouraging greater NAM adoption within drug development and their inclusion in regulatory guidelines. A specific recommendation was that pharmaceutical companies should be more transparent about how they use NAMs in-house. As well as giving guidance for the four organ systems, the maps provide a template that could be used for additional organ safety testing contexts. Moreover, their conversion to an interactive format would enable users to drill down to the detail necessary to answer specific scientific and regulatory questions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Altex-Alternatives To Animal Experimentation
Altex-Alternatives To Animal Experimentation MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
7.70
自引率
8.90%
发文量
89
审稿时长
2 months
期刊介绍: ALTEX publishes original articles, short communications, reviews, as well as news and comments and meeting reports. Manuscripts submitted to ALTEX are evaluated by two expert reviewers. The evaluation takes into account the scientific merit of a manuscript and its contribution to animal welfare and the 3R principle.
期刊最新文献
Systematic analysis of read-across adaptations in testing proposal evaluations by the European Chemicals Agency. Impact of gut permeability on estimation of oral bioavailability for chemicals in commerce and the environment. Software tools for systematic review literature screening and data extraction: Qualitative user experiences from succinct formal tests. The Virtual Human Platform for Safety Assessment (VHP4Safety) project: Next generation chemical safety assessment based on human data. Characterization of the C17.2 cell line as testing system for endocrine disruption-induced developmental neurotoxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1